A new law intended to promote collaborative research may end up costing the biotech industry more and inhibiting innovation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Mowery, C., Nelson, R.R., Sampat, B.N. & Ziedonis, A.A. Ivory Tower and Industrial Innovation: University-Industry Technology Transfer Before and After the Bayh-Dole Act. (Stanford Business Books, Stanford, CA, 2004).
Shapiro, C. Navigating the patent thicket: cross licenses, patent pools, and standard setting, in Innovation Policy and the Economy (eds. Jeffe, A., Lerner, J. & Stern, S.) 119–150 (MIT Press, Cambridge, MA, 2001).
Heller, M.A. & Eisenberg, R.S. Science 280, 698–701 (1998).
National Research Council. Committee on Intellectual Property Rights in Genomic and Protein Research and Innovation. Reaping the Benefits of Genomic and Proteomic Research: Intellectual Property Rights, Innovation, and Public Health (National Academies Press, Washington, DC, 2006).
Cooperative Research and Technology Enhancement Act of 2004 (the CREATE Act), P.L. 108-453.
Madey v. Duke University, 307 F.3d 1351 (Fed. Cir. 2002), cert. denied 123 S. Ct. 2639 (2003).
Walsh, J.P., Cohen, W.M. & Arora, A. Science 299, 1021 (2003).
The President's Council of Advisors on Science and Technology. Report on technology transfer of federally funded R&D (May 15, 2003). <http://www.ostp.gov/PCAST/pcast.html>
Boettiger, S. & Bennett, A.B. Nat. Biotechnol. 24, 320–323 (2006).
Oddzon Products, Inc. v. Just Toys, Inc. et al., 122 F.3d 1396 (Fed. Cir. 1997).
Thorne, L.W., Ergenzinger, E.R. & Spruill, W.M. Nat. Biotechnol. 22, 901–902 (2004).
Cukier, K.N. Nat. Biotechnol. 24, 249–251 (2006).
Acknowledgements
The views presented are those of the authors and do not represent the policy or opinion of the government of the United States or any of its agencies. The authors are grateful to Paul Lombardo and Jonathan Moreno for their comments and suggestions on this article. This work was supported by funds provided by the Dean of the University of Virginia School of Medicine.
Author information
Authors and Affiliations
Author notes
Ann E. Mills, Donna T. Chen and Patti M. Tereskerz are at the Program in Ethics and Policy in Health Care at the Center for Biomedical Ethics, University of Virginia School of Medicine, P.O. Box 800758, Charlottesville, Virginia 22908, USA. amh2r@virginia.edu
- John J Gillon Jr
Rights and permissions
About this article
Cite this article
Mills, A., Chen, D., Gillon, J. et al. The CREATE Act: increasing costs associated with the biotech industry?. Nat Biotechnol 24, 785–786 (2006). https://doi.org/10.1038/nbt0706-785
Issue Date:
DOI: https://doi.org/10.1038/nbt0706-785
